Compare ALV & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALV | ABVX |
|---|---|---|
| Founded | 1953 | 2013 |
| Country | Sweden | France |
| Employees | 65200 | 67 |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 9.7B |
| IPO Year | N/A | N/A |
| Metric | ALV | ABVX |
|---|---|---|
| Price | $110.66 | $118.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $134.40 | $131.31 |
| AVG Volume (30 Days) | 626.5K | ★ 882.8K |
| Earning Date | 04-17-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.55 | $70.74 |
| Revenue Next Year | $3.47 | $3,694.18 |
| P/E Ratio | $13.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $77.73 | $5.20 |
| 52 Week High | $130.14 | $148.83 |
| Indicator | ALV | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 52.48 |
| Support Level | $99.80 | $105.48 |
| Resistance Level | $128.33 | $130.20 |
| Average True Range (ATR) | 2.36 | 5.76 |
| MACD | 1.20 | 0.83 |
| Stochastic Oscillator | 81.94 | 66.92 |
Autoliv Inc is a developer, manufacturer, and supplier of passive safety systems to the automotive industry with a broad range of product offerings. Its product portfolio includes passive safety systems for commercial vehicles, battery cut-off switches, safety solutions for riders of motorcycles and bikes, airbags (including steering wheels and inflators), seatbelts, etc. Geographically, the group operates in the Americas, Europe, China, and Asia, excluding China, of which the maximum revenue is generated from its business in the Americas.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.